Plasma nanoDSF Denaturation Profile at Baseline Is Predictive of Glioblastoma EGFR Status.
Rémi EyraudStéphane AyachePhilipp O TsvetkovShanmugha Sri KalidindiViktoriia E BaksheevaSébastien BoissonneauCarine Jiguet-JiglaireRomain AppayIsabelle Nanni-MetellusOlivier ChinotFrançois DevredEmeline TabouretPublished in: Cancers (2023)
Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor in adults. Recently, we demonstrated that plasma denaturation profiles of glioblastoma patients obtained using Differential Scanning Fluorimetry can be automatically distinguished from healthy controls with the help of Artificial Intelligence (AI). Here, we used a set of machine-learning algorithms to automatically classify plasma denaturation profiles of glioblastoma patients according to their EGFR status. We found that Adaboost AI is able to discriminate EGFR alterations in GBM with an 81.5% accuracy. Our study shows that the use of these plasma denaturation profiles could answer the unmet neuro-oncology need for diagnostic predictive biomarker in combination with brain MRI and clinical data, in order to allow for a rapid orientation of patients for a definitive pathological diagnosis and then treatment. We complete this study by showing that discriminating another mutation, MGMT, seems harder, and that post-surgery monitoring using our approach is not conclusive in the 48 h that follow the surgery.
Keyphrases
- artificial intelligence
- machine learning
- end stage renal disease
- small cell lung cancer
- ejection fraction
- chronic kidney disease
- prognostic factors
- epidermal growth factor receptor
- peritoneal dialysis
- minimally invasive
- deep learning
- computed tomography
- magnetic resonance imaging
- squamous cell carcinoma
- palliative care
- coronary artery bypass
- coronary artery disease
- multiple sclerosis
- radiation therapy
- patient reported
- surgical site infection
- data analysis
- diffusion weighted imaging